DARK SECRETS: Aurinia pharmaceuticals inc org - The Real Truth

Is Aurinia Pharmaceuticals Poised for Growth in the Biotech Space?

Aurinia Pharmaceuticals (AUPH) released its third-quarter results, reporting solid revenue growth and robust cash flow from operations. Solid demand for its product offerings, restructuring strategies, and sound financials remain key drivers of the company’s growth and success. So, let’s analyze whether AUPH is a buy today. Read more to find…

StockNews.com · Jan 14, 2025

Top 4 Pharma Stocks to Consider This Month

With growing medical needs globally, R&D initiatives, and rapid adoption of emerging technologies like genAI, the pharma industry is well-poised to experience robust expansion. Thus, investors could consider buying top pharma stocks MEI Pharma (MEIP), Hypera (HYPMY), Aurinia Pharmaceuticals (AUPH), and Bayer (BAYRY) this month. Read on.

StockNews.com · May 13, 2024

Why Aurinia Pharmaceuticals Shares Are Falling Today

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is trading significantly lower Monday after the company reported declining fourth-quarter financial results on a year-over-year basis. 

Benzinga · Feb 28, 2022